Bottom line
Is PSCH a good fund? The bottom line
PSCH is an index health care sector ETF from Invesco.
Its expense ratio is 0.29% — about $29 a year on every $10,000 invested, cheaper than 94% of health care sector funds we track.
It returned +3.8% over one year, +0.6% a year over five years, +8.4% a year over ten (as of Dec 31, 2024, per its prospectus).
With $131 million in net assets and 81 holdings, its largest position is Invesco Private Prime Fund (21.5%) and the top 10 make up 59.8% of the portfolio.
What stands out
- Low cost: cheaper than 94% of health care sector peers
What to watch
- 5-year return in the bottom quarter of its category
- Concentrated: top 10 holdings are 59.8% of assets
Updated Nov 19, 2026
What PSCH invests in
The Invesco S&P SmallCap Health Care ETF (the Fund) seeks to track the investment results (before fees and expenses) of the S&P SmallCap 600 Capped Health Care Index (the Underlying Index).
The Fund generally will invest at least 90% of its total assets in the securities that comprise the Underlying Index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices, LLC (the Index Provider) compiles, maintains and calculates the Underlying Index, which is designed to measure the performance of securities of small-capitalization U.S. companies in the health care sector, as defined by the Global Industry Classification Standard (GICS ). These companies are principally engaged in the business of providing healthcare-related products, facilities, technology, supplies, and equipment and services, including in areas such as biotechnology, pharmaceuticals and life sciences. The Underlying Index selects constituents from the S&P SmallCap 600 Index, which is comprised of common stocks of approximately 600 small-capitalization companies that generally…
From the fund's prospectus (filed Dec 18, 2025).
PSCH performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| PSCH | +3.8% | +0.6% | +8.4% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2024
What PSCH costs
On a $10,000 investment, PSCH's 0.29% expense ratio costs about $29 a year. The prospectus estimates $368 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
PSCH top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Invesco Private Prime Fund | 21.48% |
| 2 | Invesco Private Government Fund | 8.27% |
| 3 | Molina Healthcare, Inc. | 4.77% |
| 4 | BrightSpring Health Services, Inc. | 4.35% |
| 5 | Krystal Biotech, Inc. | 4.25% |
| 6 | Alkermes PLC | 3.71% |
| 7 | Corcept Therapeutics Inc. | 3.47% |
| 8 | Glaukos Corp. | 3.17% |
| 9 | PTC Therapeutics, Inc. | 3.16% |
| 10 | Protagonist Therapeutics, Inc. | 3.12% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 59.8% of the fund. See all top 25 holdings and asset mix →